News
Discover the latest news from
ID SOLUTIONS
The Role of Sport in Reducing the Risk of Cancer Recurrence
Le rôle du sport dans la réduction du risque de récidive
MEDICA 2024 : Meet the Experts from Bioshare Solutions
Meet Bioshare Solutions at MEDICA 2024.
ID SOLUTIONS Oncology at the SFMPP Congress
Meet ID SOLUTIONS Oncology & our partner Diatech Pharmacogenetics at the SFMPP !
Event : POLA WORKSHOP
Meet ID SOLUTIONS Oncology at the Oligodendroglioma workshop.
ASCO 2024 Congress: meet the ID SOLUTIONS Oncology team!
Meeting between oncology professionals and creating partnerships (…)
Liquid biopsy follow-up
Patients with advanced ER+/HER2- breast cancer treated with endocrine therapy are at greater risk of developing resistance mutations in various genes, including Estrogen Receptor 1 (ESR1).
February 4th – WORLD CANCER DAY
ID SOLUTIONS supports and encourages all initiatives in the fight against cancer.
Nos dernières études cliniques
Organisme Promoteur
Organisme Promoteur
Organes
Organes
Date de publication
12/11/2022
A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharma cokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) with RGFR or HER2
Organisme Promoteur
Organisme Promoteur
Organes
Organes
Date de publication
12/11/2022
A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharma cokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) with RGFR or HER2
Organisme Promoteur
Organisme Promoteur
Organes
Organes
Date de publication
12/11/2022
A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharma cokinetics and Anti-tumor Efficacy of DZD9008 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) with RGFR or HER2